Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis in hematologic malignancies.

T M Moehler1, A D Ho, H Goldschmidt

  • 1Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.

Critical Reviews in Oncology/Hematology
|March 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

An automated approach to determine antibody endpoint titers for COVID-19 by an enzyme-linked immunosorbent assay.

Immunohematology·2021
Same author

Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD.

Bone marrow transplantation·2017
Same author

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.

BMC cancer·2017
Same author

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.

Oncogenesis·2017
Same author

GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.

Bone marrow transplantation·2017
Same journal

Opportunities and Challenges of Dihydrodiol dehydrogenase Expression in Hepatocellular carcinoma.

Critical reviews in oncology/hematology·2026
Same journal

Ferroptosis in Glioblastoma: Molecular Determinants, Immune Crosstalk, and Therapeutic Opportunities.

Critical reviews in oncology/hematology·2026
Same journal

Beyond Oncogenesis: The emerging role of EZH2 in Tumor Microenvironment.

Critical reviews in oncology/hematology·2026
Same journal

Cross-Scale Bioanalytical Integration for Decoding Tumour Regulatory Plasticity in Oncology.

Critical reviews in oncology/hematology·2026
Same journal

Organoids in Biliary Tract Cancers: Advances in Modeling Strategies and Translational Applications.

Critical reviews in oncology/hematology·2026
Same journal

Corrigendum to "Management of atypical cartilaginous tumors (ACT): An Italian Sarcoma Group (ISG) consensus document" [Crit. Rev. Oncol. Hematol. 223 (2026) 105358].

Critical reviews in oncology/hematology·2026
See all related articles

Angiogenesis, the formation of new blood vessels, is crucial in solid tumors and increasingly recognized in blood cancers. Antiangiogenic therapies show promise for treating hematologic malignancies like leukemia and multiple myeloma.

Area of Science:

  • Oncology
  • Hematology
  • Vascular Biology

Background:

  • Angiogenesis, the formation of new capillaries from existing vessels, is vital for solid tumor progression.
  • A similar role for angiogenesis is now recognized in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma.
  • Expression of angiogenic factors like vascular endothelial growth factor (VEGF) correlates with disease characteristics and prognosis in certain blood cancers.

Purpose of the Study:

  • To review the role of angiogenesis in hematologic malignancies.
  • To discuss the therapeutic potential of antiangiogenic strategies in blood cancers.
  • To highlight ongoing clinical research in antiangiogenic treatments for hematologic neoplasms.

Main Methods:

  • Literature review of studies on angiogenesis in hematologic malignancies.

Related Experiment Videos

  • Analysis of the correlation between angiogenic factors and clinical outcomes.
  • Evaluation of the efficacy of antiangiogenic drugs like thalidomide and VEGF inhibitors.

    • Main Results:

    • Increased bone marrow vascularity in multiple myeloma is linked to poorer survival.
    • Thalidomide demonstrates efficacy in multiple myeloma, myelodysplastic syndrome, and acute myeloid leukemia due to its antiangiogenic and cytotoxic effects.
    • Preliminary data suggest activity of VEGF-tyrosine kinase inhibitors in acute myeloid leukemia.

    Conclusions:

    • Angiogenesis is a significant factor in the progression of hematologic malignancies.
    • Antiangiogenic therapies represent a promising treatment avenue for various blood cancers.
    • Future research will focus on optimizing antiangiogenic treatment strategies and patient selection for hematologic neoplasms.